(Q54513818)

30 May 2018

title

JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. (English)

1 reference

30 May 2018

author

Christian Beyer

5

1 reference

30 May 2018

Michal Tomčík

object named as

Michal Tomcik

2

0 references

Georg Schett

12

object named as

Georg Schett

1 reference

30 May 2018

Clara Dees

1

1 reference

30 May 2018

Katrin Palumbo-Zerr

3

1 reference

30 May 2018

Alfiya Distler

4

1 reference

30 May 2018

Veronika Lang

6

1 reference

30 May 2018

Angelika Horn

7

1 reference

30 May 2018

Pawel Zerr

8

1 reference

30 May 2018

Jochen Zwerina

9

1 reference

30 May 2018

Kolja Gelse

10

1 reference

30 May 2018

Oliver Distler

11

1 reference

30 May 2018

Jörg H W Distler

13

1 reference

30 May 2018

publication date

1 September 2012

1 reference

30 May 2018

published in

Arthritis and Rheumatism

1 reference

30 May 2018

volume

64

1 reference

30 May 2018

issue

9

1 reference

30 May 2018

page(s)

3006-3015

1 reference

30 May 2018

1 reference

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

21 January 2018

1 reference

Systemic sclerosis: a prototypic multisystem fibrotic disorder

21 January 2018

1 reference

21 January 2018

The Janus kinases (Jaks)

1 reference

Hematopoietic cytokine receptor signaling

21 January 2018

1 reference

JAK/STAT signal transduction: regulators and implication in hematological malignancies

21 January 2018

1 reference

Therapeutic potential of JAK2 inhibitors

21 January 2018

1 reference

Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts

21 January 2018

1 reference

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis

21 January 2018

1 reference

The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis

21 January 2018

1 reference

Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis.

21 January 2018

1 reference

Platelet-derived serotonin links vascular disease and tissue fibrosis

21 January 2018

1 reference

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

21 January 2018

1 reference

Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis

21 January 2018

1 reference

Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.

21 January 2018

1 reference

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

21 January 2018

1 reference

Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells

21 January 2018

1 reference

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

21 January 2018

1 reference

Animal models of systemic sclerosis: prospects and limitations

21 January 2018

1 reference

A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy

21 January 2018

1 reference

Suppressor of cytokine signaling-1 reduces high glucose-induced TGF-beta1 and fibronectin synthesis in human mesangial cells

21 January 2018

1 reference

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

21 January 2018

1 reference

JAK2 inhibitors: what's the true therapeutic potential?

21 January 2018

1 reference

Systemic sclerosis: hypothesis-driven treatment strategies

21 January 2018

1 reference

Therapies for interstitial lung disease: past, present and future

21 January 2018

1 reference

Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.34500

1 reference

30 May 2018

release_h4v5dd6hjbfezlnycycusfekqi

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h4v5dd6hjbfezlnycycusfekqi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

30 May 2018